The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.
Abstract
This study was designed to assess the role of dosage of chemotherapy for treatment of metastatic breast cancer. One hundred thirty-three patients without prior chemotherapy for metastatic disease were randomly allocated to receive two different dose levels of cyclophosphamide (C), methotrexate (M), and fluorouracil (F), administered intravenously (IV) every 3 weeks. Patients were stratified by sites of disease (visceral, bone, or soft-tissue dominant) and by interval from primary surgery to first recurrence. Doses on the higher-dose arm were 600 mg/m2 (C,F) and 40 mg/m2 (M) with escalation if possible; doses on the lower-dose arm were 300 mg/m2 (C,F) and 20 mg/m2 (M) without escalation. Patients who failed to respond to lower-dose CMF were crossed over to the higher-dose arm. Patients randomized to the higher-dose arm had longer survival measured from initiation of chemotherapy (median survival, 15.6 months v 12.8 months, P = .026 by log-rank test), but the effect of dose was of borderline significance (P approximately 0.12) when adjusted for a chance imbalance between the two arms in the time from first relapse to randomization, using the Cox proportional hazards model. Response rates (International Union Against Cancer [UICC] criteria) for patients with measurable disease were higher-dose arm: 16/53 (30%) and lower-dose arm: 6/53 (11%), (P = .03). Only one of 37 patients responded on crossover from the lower- to the higher-dose arm. Patients experienced more vomiting, myelosuppression, conjunctivitis, and alopecia when receiving higher doses of chemotherapy. A series of 34 linear analogue self-assessment scales were used to make detailed quality of life assessments on a subset of 49 patients. These scales confirmed greater toxicity in the immediate posttreatment period, but also a trend to improvement in general health and some disease-related indices, in patients receiving higher-dose chemotherapy. This trial suggests that better palliation is achieved by using full-dose chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Hryniuk, W., & Bush, H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1281 · Cited by 885
Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
Coates, A., Gebski, V., Bishop, J. F., Jeal, P. N., Woods, R. L., Snyder, R., Tattersall, M. H. N., Byrne, M., Harvey, V., Gill, G., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712103172402 · Cited by 537
The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
Goldie, J. H., & Coldman, A. J. (1984) · PubMed · Cited by 511
Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease
McCorkle, R., & Quint-Benoliel, J. (1983) · Social Science & Medicine · doi:10.1016/0277-9536(83)90348-9 · Cited by 329
The development of a method for assessing the quality of life of cancer patients
Selby, P. J., Chapman, J. A., Etazadi-Amoli, J., Dalley, D., & Boyd, N. F. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.134 · Cited by 277
Self-citationWarr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Self-citationShort term high density systemic therapy for metastatic breast cancer
Tormey, D. C., Kline, J. C., Palta, M., Davis, T. E., Love, R. R., & Carbone, P. P. (1985) · Breast Cancer Research and Treatment · doi:10.1007/bf01805992 · Cited by 22
Quality of life measurement in breast cancer patients
Bell, D., Tannock, I. F., & Boyd, N. F. (1985) · British Journal of Cancer · doi:10.1038/bjc.1985.81 · Cited by 21
Self-citation
Cited by
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.9.652 · Cited by 584
Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Metadata
- Authors
- Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., & Sutherland, H.
- Venue
- Journal of Clinical Oncology
- Published
- 1988-09
- Volume
- 6
- Issue
- 9
- Pages
- 1377-1387
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2253920138
- Cited by
- 348
- References
- 8
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.1988.6.9.1377
- The paper
- Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., & Sutherland, H. (1988). A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1988.6.9.1377
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.